INSTITUTE OF DRUG TECHNOLOGY AUSTRALIA LIMITED

1
INSTITUTE OF DRUG TECHNOLOGY AUSTRALIA LIMITED

• Dr Graeme L Blackman
• CHAIRMAN AND MANAGING DIRECTOR

IDT

2
OUTSOURCING

• Trend to increase outsourcing by major
  pharmaceutical companies
• More capital in core competencies
• Less capital in intensive manufacturing
• Speed to market
• Second suppliers
• Small and medium companies must outsource
  manufacturing and clinical trials due to lack of
  infrastructure and skill

IDT

3
STRATEGIC ALLIANCES

• Multi-national Innovator Companies
• Virtual Innovator Companies
• Generic Manufacturing Companies

IDT

4
IDT BUSINESS AREAS

• A MANUFACTURING
• (1) APIs Commercial manufacture of selected
  active pharmaceutical ingredients
• (2) Finished dosage forms Commercial
  manufacture of selected finished products
  including tablets and capsules

IDT

5
IDT API Manufacturing Facilities

• 2000 Litre FACILITY
• 63 Litre FACILITY
• 250 Litre CONTAINMENT FACILITY
• 100 Litre and 400 litre CONTAINMENT FACILITIES
• 60 Litre CONTAINMENT FACILITY
• 20-50 Litre CONTAINMENT FACILITIES (x8)
• BIOTECHNOLOGY FACILITY

IDT

6
API Manufacturing Plant

IDT

7
High Containment Capsule Production Plant

IDT

8
High Containment Sterile Freeze Drying Plant

IDT

9
IDT BUSINESS AREAS

• B DRUG DEVELOPMENT
• RD for local and international companies for new
  and improved pharmaceutical products. API,
  Analytical and Drug Products
• (2) CLINICAL Early stage clinical development
  through CMAX clinical trials unit

IDT

10
IDT High Containment RD facilities

IDT

11
IDT High Containment Tablet Coating Development
Facility

IDT

12
CMAX CLINICAL TRIAL SERVICES

• Principal Investigator selection
• Phase I trial management
• Site selection for Phase II to III studies
• Recruitment of specific patient populations

IDT

13
KEY BUSINESS DRIVERS

• increased finished product manufacturing
• increased fee for service drug development
  activity
• increased clinical trial activity within our
  Adelaide based CMAX unit

IDT

14
KEY FINANCIAL INFORMATION2006

• Full Year Revenue 25 million
• Full year NPAT 3.6 million
• (Second Half Year Profit Before Tax record 4.1
  million)
• Dividend Payout Ratio 95

IDT

15
Revenue (000)
IDT

16
Profit After Tax
IDT

17
EBIT MARGIN ()
IDT

18
Shareholders Equity(000)
IDT

19
Dividend per share (cents)
IDT

20
Capital Expenditure (000)
IDT

21

Dr Graeme L Blackman Chairman and Managing
Director Institute of Drug Technology Australia
Limited Tel [phone] Fax
61-3-9801-8773 E-mail gblackman_at_idtaus.com.au
IDT